KONVOMEP (omeprazole and sodium bicarbonate) by R-Pharm US is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the h+/k+ atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for active benign gastric ulcer ( ), risk of upper gastrointestinal (gi) bleeding in critically ill patients ( ). First approved in 2022.
Drug data last refreshed 1h ago · AI intelligence enriched 2d ago
KONVOMEP is an oral suspension combining omeprazole (a proton pump inhibitor) and sodium bicarbonate, approved in August 2022 for active benign gastric ulcers and prevention of upper GI bleeding in critically ill patients. It works by suppressing gastric acid secretion through specific inhibition of the H+/K+ ATPase enzyme system at the gastric parietal cell, blocking the final step of acid production.
Product is in peak lifecycle phase with modest Part D uptake (4,389 claims in 2023), suggesting stable but niche market positioning with small commercial footprint.
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has…
Worked on KONVOMEP at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moKONVOMEP offers career opportunity within a specialized, niche franchise with modest commercial scale but growing market visibility in critical care and gastroenterology. Working on this product as it moves through peak lifecycle provides exposure to safety signal management (renal risk), market penetration in institutional settings, and long-term brand stewardship before generic entry.